Quotes 5-day view Delayed Nasdaq
10/20/2020
10/21/2020
10/22/2020
10/23/2020
10/26/2020
Date
576.63(c)
572.4(c)
575.73(c)
579.81(c)
585.685 Last
637 682
493 964
468 945
565 966
305 807 Volume
-1.12% -0.73% +0.58% +0.71% +1.01% Change
Sales 2020
8 278 M - -
Net income 2020
2 973 M - -
Net cash position 2020
5 675 M - -
P/E ratio 2020
21,3x
Yield 2020
-
Sales 2021
9 889 M - -
Net income 2021
3 680 M - -
Net cash position 2021
9 710 M - -
P/E ratio 2021
16,5x
Yield 2021
-
Capitalization
61 014 M 61 014 M -
EV / Sales 2020
6,68x
EV / Sales 2021
5,19x
Nbr of Employees
8 142
Free-Float
83,3%
Regeneron Pharmaceuticals specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Sales break down by activity as follows:
- sales of products (61.5%);
- supply of collaborative services (33.3%): working with Sanofi (54.5% of sales) and Bayer (45.5%);
- sales of technology licenses (5.2%). The group also provides subcontracting...
Notations Surperformance© of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
All news about REGENERON PHARMACEUTICALS
News in other languages on REGENERON PHARMACEUTICALS
Lilly hires external adviser for COVID-19 drug plant problems
Chart REGENERON PHARMACEUTICALS
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends REGENERON PHARMACEUTICALS
Short Term Mid-Term Long Term Trends Neutral Neutral Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
26
Average target price
671,83 $
Last Close Price
579,81 $
Spread / Highest target
38,0%
Spread / Average Target
15,9%
Spread / Lowest Target
-13,8%
Please enable JavaScript in your browser's settings to use dynamic charts.
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
